RSD1235
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation, Atrial Flutter
Trial Timeline
Jun 1, 2004 → Feb 1, 2007
NCT ID
NCT00125320About RSD1235
RSD1235 is a phase 3 stage product being developed by Astellas Pharma for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT00125320. Target conditions include Atrial Fibrillation, Atrial Flutter.
What happened to similar drugs?
20 of 20 similar drugs in Atrial Fibrillation were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00281554 | Phase 3 | Completed |
| NCT00125320 | Phase 3 | Completed |
Competing Products
20 competing products in Atrial Fibrillation